- Completed enrollment of more than 2,100 subjects at multiple sites in the United States and Canada for SAKURA open-label safety Phase 3 study of RT002 injectable for the treatment of glabellar (frown) lines; Revance expects to complete the study in the second half of 2018.
- SAKURA 1 & 2 Phase 3 pivotal trials remain on track to report topline results before the end of 2017.
- Completed enrollment of the Phase 2 trial of RT002 injectable in the management of plantar fasciitis in October of 2017. Revance remains on track to report topline 8-week safety and efficacy results at year-end.
- Scheduled meeting for the fourth quarter of 2017 with the U.S. Food & Drug Administration to review the data from the Phase 2 trial of RT002 for the treatment of moderate to severe isolated cervical dystonia and to determine next steps for the program.
- Announced the appointment of Mark Foley, an industry veteran with more than 25 years of operational and investment experience in the healthcare arena, to Revance's Board of Directors and Todd Zavodnick, a 20-year industry leader, joining our executive team as Chief Commercial Officer and President, Aesthetics & Therapeutics.
Summary Financial ResultsCash and investments as of September 30, 2017 were $153.4 million. Research and development expenses for the three and nine months ended September 30, 2017 were $21.6 million and $59.4 million compared to $10.3 million and $37.9 million for the same periods in 2016, respectively. The change in research and development expenses is primarily due to increased clinical trial activity for RT002 injectable, including the SAKURA Phase 3 program, the plantar fasciitis Phase 2 trial, and the cervical dystonia Phase 2 trial, along with increased pre-commercial manufacturing activities. General and administrative expenses for the three and nine months ended September 30, 2017 were $9.1 million and $25.5 million compared to $7.5 million and $22.0 million for the same periods in 2016, respectively. The increase in general and administrative expenses is primarily due to increased personnel, pre-commercial, and information technology expenses. Total operating expenses for the three and nine months ended September 30, 2017 were $30.8 million and $84.9 million compared to $17.8 million and $61.8 million for the same periods in 2016, respectively. Stock-based compensation for the three and nine months ended September 30, 2017 was $3.1 million and $9.8 million, respectively. When excluding depreciation and stock-based compensation, total operating expenses for the three and nine months ended September 30, 2017 were $27.3 million and $74.0 million, respectively. Net loss for the three and nine months ended September 30, 2017 was $30.7 million and $84.7 million compared to $18.0 million and $62.5 million for the same periods in 2016, respectively. 2017 Financial Outlook Revance reaffirmed its financial guidance provided in January 2017. Revance expects cash burn for 2017 to be in the range of $102 to $112 million. Revance expects 2017 GAAP operating expense to be in the range of $108 to $119 million, which when excluding depreciation of $1 to $2 million and estimated stock-based compensation of $13 to $15 million, results in projected 2017 non-GAAP operating expense of $94 to $102 million. Revance anticipates 2017 GAAP research and development expense to be in the range of $75 to $83 million, which when excluding depreciation of $1 to $2 million and estimated stock-based compensation of $5 to $6 million, results in projected 2017 non-GAAP research and development expense of $69 to $75 million.
Conference CallIndividuals interested in listening to the conference call today, November 2, at 1:30pm PT/4:30pm ET, may do so by dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for international callers and reference conference ID: 99298055; or from the webcast link in the investor relations section of the Company's website at: http://investors.revance.com/index.cfm. A replay of the call will be available beginning today at 4:30pm PT/7:30pm ET through 4:30pm PT/7:30pm ET on November 3, 2017. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference conference ID: 99298055. The webcast will be available in the investor relations section on the Company's website for 30 days following the completion of the call. About Revance Therapeutics, Inc. Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology, orthopedics and neurology. Revance's science is based upon a proprietary peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. The company holds worldwide rights to RT002 injectable and RT001 topical and the pharmaceutical uses of its proprietary peptide technology platform. More information on Revance may be found at www.revance.com. "Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc. Forward-Looking Statements This press release contains forward-looking statements, including statements related to Revance Therapeutics' 2017 Financial Outlook and other financial performance, the process and timing of, and ability to complete, current and anticipated future clinical development of our investigational drug product candidates, including but not limited to initiation and design of clinical studies for current and future indications, related results and reporting of such results; statements about our business strategy, timeline and other goals and market for our anticipated products, plans and prospects; and statements about our ability to obtain regulatory approval; and potential benefits of our drug product candidates and our technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited to: the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; our ability to obtain funding for our operations; our plans to research, develop, and commercialize our drug product candidates; our ability to achieve market acceptance of our drug product candidates; unanticipated costs or delays in research, development, and commercialization efforts; the applicability of clinical study results to actual outcomes; the size and growth potential of the markets for our drug product candidates; our ability to successfully commercialize our drug product candidates and the timing of commercialization activities; the rate and degree of market acceptance of our drug product candidates; our ability to develop sales and marketing capabilities; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Revance's periodic filings with the Securities and Exchange Commission (the "SEC"), including factors described in the section entitled "Risk Factors" of our quarterly report on Form 10-Q filed August 4, 2017. These forward-looking statements speak only as of the date hereof. Revance disclaims any obligation to update these forward-looking statements. Use of Non-GAAP Financial Measures Revance has presented certain non-GAAP financial measures in this release. This release and the reconciliation tables included herein include total non-GAAP operating expense and non-GAAP R&D expense, both of which exclude depreciation and stock-based compensation. Revance excludes depreciation costs and stock-based compensation expense because management believes the exclusion of these items is helpful to investors to evaluate Revance's recurring operational performance. Revance management uses these non-GAAP financial measures to monitor and evaluate its operating results and trends on an on-going basis, and internally for operating, budgeting and financial planning purposes. The non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for or superior to GAAP results.
|REVANCE THERAPEUTICS, INC. Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) (Unaudited)|
|September 30,||December 31,|
|Cash and cash equivalents||$||56,323||$||63,502|
|Prepaid expenses and other current assets||2,827||7,167|
|Total current assets||156,267||192,695|
|Property and equipment, net||11,500||10,585|
|Other non-current assets||836||500|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Accruals and other current liabilities||12,069||12,418|
|Financing obligations, current portion||2,727||3,475|
|Total current liabilities||21,476||19,647|
|Financing obligations, net of current portion||—||1,872|
|Derivative liability associated with Medicis settlement||2,233||2,022|
|Other non-current liabilities||—||100|
|Commitments and Contingencies|
|Common stock, par value $0.001 per share — 95,000,000 shares authorized as ofSeptember 30, 2017 and December 31, 2016; 30,935,094 and 28,648,954 sharesissued and outstanding as of September 30, 2017 and December 31, 2016,respectively||31||29|
|Additional paid-in capital||648,329||598,630|
|Accumulated other comprehensive loss||(43||)||(45||)|
|TOTAL STOCKHOLDERS' EQUITY||142,056||177,071|
|TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY||$||169,183||$||204,360|
|REVANCE THERAPEUTICS, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited)|
|Three Months Ended September 30,||Nine Months Ended September 30,|
|Research and development||21,643||10,296||59,357||37,851|
|General and administrative||9,148||7,502||25,511||21,975|
|Loss on impairment||—||—||—||1,949|
|Total operating expenses||30,791||17,798||84,868||61,775|
|Loss from operations||(30,716||)||(17,723||)||(84,643||)||(61,550||)|
|Change in fair value of derivative liability associated with Medicissettlement||(44||)||(167||)||(211||)||(595||)|
|Other expense, net||(128||)||(138||)||(386||)||(406||)|
|Unrealized gain (loss) on available for sale securities||72||(132||)||3||56|
|Net loss attributable to common stockholders:|
|Basic and Diluted||$||(30,651||)||$||(17,978||)||$||(84,680||)||$||(62,468||)|
|Net loss per share attributable to common stockholders:|
|Basic and Diluted||$||(1.01||)||$||(0.64||)||$||(2.86||)||$||(2.22||)|
|Weighted-average number of shares used in computing net loss pershare attributable to common stockholders:|
|Basic and Diluted||30,270,260||28,160,458||29,623,805||28,085,541|
|Revance Therapeutics, Inc. 2017 Financial Results (Unaudited)|
|Reconciliation of GAAP Operating Expense to Non-GAAP Operating Expense (In thousands)|
|Three Months Ended||Nine Months Ended|
|September 30, 2017||September 30, 2017|
|GAAP operating expense||$||30,791||$||84,868|
|Non-GAAP operating expense||$||27,270||$||73,952|
|Revance Therapeutics, Inc. 2017 Financial Guidance|
|Reconciliation of GAAP Operating Expense to Non-GAAP Operating Expense (In thousands)|
|GAAP operating expense||$||108,000||$||119,000|
|Non-GAAP operating expense||$||94,000||$||102,000|
|Reconciliation of GAAP R&D Expense to Non-GAAP R&D Expense (In thousands)|
|GAAP R&D expense||$||75,000||$||83,000|
|Non-GAAP R&D expense||$||69,000||$||75,000|